Henry Schein, Inc. $HSIC Shares Sold by Marathon Asset Management Ltd

Marathon Asset Management Ltd lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 8.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 156,665 shares of the company’s stock after selling 15,223 shares during the quarter. Marathon Asset Management Ltd’s holdings in Henry Schein were worth $11,841,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its stake in shares of Henry Schein by 2.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 86,264 shares of the company’s stock valued at $6,520,000 after acquiring an additional 1,717 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Henry Schein by 1.3% during the 4th quarter. Handelsbanken Fonder AB now owns 30,600 shares of the company’s stock valued at $2,313,000 after acquiring an additional 400 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Henry Schein by 3.9% during the 4th quarter. ProShare Advisors LLC now owns 20,147 shares of the company’s stock valued at $1,523,000 after acquiring an additional 758 shares during the last quarter. North Dakota State Investment Board acquired a new position in shares of Henry Schein during the 4th quarter valued at about $280,000. Finally, Beese Fulmer Investment Management Inc. increased its stake in shares of Henry Schein by 55.2% during the 4th quarter. Beese Fulmer Investment Management Inc. now owns 5,903 shares of the company’s stock valued at $446,000 after acquiring an additional 2,100 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HSIC. Mizuho decreased their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Barrington Research set a $97.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Wells Fargo & Company boosted their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Citigroup began coverage on Henry Schein in a report on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price for the company. Finally, UBS Group reiterated a “neutral” rating and set a $85.00 target price (down from $87.00) on shares of Henry Schein in a report on Wednesday, May 6th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $86.83.

Insider Transactions at Henry Schein

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares in the company, valued at $1,217,563.20. This represents a 15.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total value of $228,543.84. Following the completion of the transaction, the director owned 21,961 shares of the company’s stock, valued at approximately $1,764,785.96. This represents a 11.47% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 105,911 shares of company stock worth $8,574,982 over the last 90 days. 0.89% of the stock is owned by corporate insiders.

Henry Schein Stock Up 0.3%

NASDAQ HSIC opened at $72.92 on Wednesday. The stock has a market cap of $8.31 billion, a PE ratio of 22.03, a P/E/G ratio of 1.82 and a beta of 0.82. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The business has a 50 day moving average price of $74.54 and a two-hundred day moving average price of $75.48. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The firm had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.Henry Schein’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts predict that Henry Schein, Inc. will post 5.31 EPS for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.